STE · 8-K · 20261104PR070220

Guidance / Outlook

STERIS plc · 2026-11-04 · Importance 56 · Surprise 68 · In source text

For fiscal 2027, STERIS maintained consolidated revenue-growth expectations of 7–8% as reported and 6–7% constant-currency organic. Adjusted diluted EPS guidance increased to $11.35–$11.55 from $11.10–$11.30, including approximately $0.18 per share from year-to-date tariff refunds. The company raised its Life Sciences constant-currency organic revenue-growth outlook to 9–10% from 6–7%, while lowering Applied Sterilization Technologies guidance to 6–7% from 7–8%; Healthcare remained at 6–7%. STERIS said it will update fiscal 2027 guidance to include the proposed Xodus Medical acquisition after closing.

Key facts

• STERIS plc’s fiscal 2027 outlook estimates $1,250.0 million in operating cash flow, $450.0 million in purchases of property, plant, equipment, and intangibles, and $800.0 million in free cash flow. source
• STERIS plc plans to provide revised fiscal 2027 outlook inclusive of the proposed Xodus Medical acquisition after closing. source
• STERIS plc expects to discontinue backlog disclosure beginning in fiscal 2028 because backlog has become a less meaningful indicator of future revenue trends across the business. source
• STERIS plc raised its fiscal 2027 adjusted earnings-per-diluted-share outlook to $11.35–$11.55 from its prior range of $11.10–$11.30. source
• STERIS plc’s current fiscal 2027 constant-currency organic revenue growth outlook is 6–7% for Healthcare, 6–7% for Applied Sterilization Technologies, and 9–10% for Life Sciences. source
• STERIS plc’s fiscal 2027 second-quarter total backlog was $548.9 million, compared with $541.3 million in fiscal 2026’s second quarter. source
• STERIS plc’s fiscal 2027 revenue-growth outlook is unchanged: 7–8% as-reported growth and 6–7% constant-currency organic revenue growth. source

Impact estimates